Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) will present new open-label extension data from its Phase 3 ARGUS trial of EPX-100 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE